BIAF

News

prnewswire.comWallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offeringprnewswire.comJun 18

businesswire.combioAffinity Technologies Announces Closing of $3.2 Million Offeringbusinesswire.comJun 18

prnewswire.comWallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offeringprnewswire.comJun 17

businesswire.combioAffinity Technologies Announces Pricing of $3.2 Million Offeringbusinesswire.comJun 17

seekingalpha.combioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcriptseekingalpha.comJun 17

Trade BIAF

About bioAffinity Technologies, Inc.

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

CEO: Maria Zannes
IPO Date: Sep 1, 2022

Market Data

Open: $0.84
High: $0.8625
Low: $0.8182
Volume: 812.3K
Avg Volume: 2.3M
52W High: $13.80
52W Low: $0.693

Valuation

Market Cap: $3.8M
Enterprise Value: $2.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-9.4M
Revenue: $6.2M
Net Income: $-15M
Cash: $6.4M
Debt: $1.2M

Events

EarningsAug 19

EPS est. -2.1